Halozyme Therapeutics, Inc. (HALO)
71.30
+0.56
(+0.80%)
USD |
NASDAQ |
Jun 09, 15:31
Halozyme Therapeutics SG&A Expense (Quarterly) : 57.88M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 493.70M |
| Agenus, Inc. | 6.86M |
| Altimmune, Inc. | 8.052M |
| Lineage Cell Therapeutics, Inc. | 5.084M |
| Amgen, Inc. | 1.602B |